medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in
COVID-19 convalescent individuals

Michal A. Stanczakâ€‹1âŒ—â€‹,â€‹ â€‹David E. Saninâ€‹1âŒ—â€‹, Petya Apostolovaâ€‹1âŒ—â€‹, Gabriele Nerzâ€‹2â€‹, Dimitrios
Lampakiâ€‹2â€‹, Maike Hofmannâ€‹3â€‹, Daniel Steinmannâ€‹4â€‹, Robert Thimmeâ€‹3â€‹, Gerhard Mittlerâ€‹2â€‹,
Cornelius F. Wallerâ€‹5âŒ—â€‹*, Edward J. Pearceâ€‹1,6âŒ—â€‹* and Erika L. Pearceâ€‹1âŒ—â€‹*

1â€‹

Department of Immunometabolism, Max Planck Institute for Immunobiology and

Epigenetics, 79108 Freiburg, Germany
2â€‹

Proteomics, Max Planck Institute of Immunobiology and Epigenetics, 79108

Freiburg, Germany.
3â€‹

Department of Medicine II, University Hospital Freiburg, Faculty of Medicine,

University of Freiburg, 79106 Freiburg, Germany
4â€‹

Occupational Medical Service, Medical Center - University of Freiburg, Faculty of

Medicine, University of Freiburg, 79106 Freiburg, Germany
5â€‹

Department of Medicine I, Medical Center - University of Freiburg, Faculty of

Medicine, University of Freiburg, â€‹79106 â€‹Freiburg, Germany
6â€‹

Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany

âŒ—â€‹

equal contribution

*Corresponding author. Email: pearce@ie-freiburg.mpg.de
*Corresponding author. Email: edpearce@ie-freiburg.mpg.de
*Corresponding author. Email: cornelius.waller@uniklinik-freiburg.de
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT
Our understanding of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is still developing. We investigated seroprevalence and immune
responses in subjects professionally exposed to SARS-CoV-2 and their family
members (155 individuals; ages 5â€“79 years). Seropositivity for SARS-CoV-2 spike
glycoprotein aligned with PCR results that confirmed previous infection. Anti-spike
IgG titers remained high 60 days post-infection and did not associate with symptoms,
but spike-specific IgM did associate with malaise and fever. We found limited
household transmission, with children of infected individuals seldomly seropositive,
highlighting professional exposure as the dominant route of infection in our cohort.
We analyzed PBMCs from a subset of seropositive and seronegative adults. TLR7
agonist-activation revealed an increased population of IL-6â€‹+â€‹TNFâ€‹-â€‹IL-1Î²â€‹+â€‹ monocytes,
while SARS-CoV-2 peptide stimulation elicited IL-33, IL-6, IFNa2, and IL-23
expression in seropositive individuals. IL-33 correlated with CD4â€‹+â€‹ T cell activation in
PBMCs from convalescent subjects, and was likely due to T cell-mediated effects on
IL-33-producing cells. IL-33 is associated with pulmonary infection and chronic
diseases like asthma and COPD, but its role in COVID-19 is unknown. Analysis of
published scRNAseq data of bronchoalveolar lavage fluid (BALF) from patients with
mild to severe COVID-19 revealed a population of IL-33-producing cells that
increases with disease. Together these findings show that IL-33 production is linked
to SARS-CoV-2 infection and warrant further investigation of IL-33 in COVID-19
pathogenesis and immunity.

2

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

MAIN
We took the opportunity to study a cohort of individuals with a known professional
exposure, within a relatively small timeframe (~2â€“3 months), as the pandemic was
developing. We assessed viral transmission among these individuals and their family
members. Specifically, we used an ELISA to measure IgG and IgM titers against the
SARS-CoV-2 spike glycoproteinâ€‹1â€‹. Our study population included 155 subjects who
either tested positive for SARS-CoV-2 via PCR or were in contact with
SARS-CoV-2-infected individuals. Demographic and disease characteristics of the
study population are indicated in Supplementary Table 1. Median age was 36 years
and 98 (63.2%) were females; 99 (64.5%) had professional exposure to the virus, 44
(28.4%) were exposed within their household and 12 subjects had either multiple or
different/unknown exposure sources. Symptoms of upper respiratory tract infection
within the last 16 weeks prior to blood collection were reported by 97 (62.6%)
individuals. SARS-CoV-2 PCR testing was performed in 87 individuals, with 47
(30.3%) having a positive PCR result. We evaluated the presence and abundance of
antibodies against the spike protein of SARS-CoV-2 in the serum of the study
population, as well as in 16 historical sera collected prior to the onset of the
COVID-19 pandemic. We found highest antibody titers among individuals with a
positive SARS-CoV-2 PCR (â€‹Fig. 1aâ€‹), as well as a few cases where subjects with a
negative PCR result possessed antibodies against the viral protein (9/40). As the
date of the PCR and the collection of serum samples were separated by a median
time of 49 days, it is possible that these individuals became infected after a PCR was
carried out. Likewise, we discovered few cases (3/47) where a positive PCR result
did not associate with elevated anti-spike IgG titers.

3

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

We used the signal measured in pre-exposure sera to set a threshold to define
seropositive and borderline cases (â€‹Fig. 1aâ€‹ â€“ black and red dashed lines
respectively). This resulted in 5 borderline cases and 65 seropositive individuals. We
then probed collected sera for IgG and IgM antibodies against the spike protein and
its receptor binding domain (RBD) finding a robust correlation between these
measurements (â€‹Fig. 1bâ€“c, i â€‹andâ€‹ Extended Data Fig. 1aâ€“eâ€‹). Most seropositive
subjects reported experiencing symptoms (â€‹Fig. 1dâ€‹). We discovered only 6
asymptomatic individuals out of 65 seropositive subjects (2/8 borderline cases) who
nonetheless had high anti-spike IgG titers (â€‹Fig. 1dâ€‹) although anti-RBD IgG titers
were appreciatively lower (â€‹Fig. 1eâ€‹). We found no association between sex and
antibody titers (â€‹Fig. 1fâ€“gâ€‹). To explore possible links between clinical features and
antibody titers, we probed our data with two complementary strategies. First, we
fitted logistic regression models to reported symptoms among seropositive subjects
(â€‹Fig. 1h â€‹andâ€‹ Extended Data Fig. 1fâ€“hâ€‹), setting the symptom report (yes = 1, no = 0)
as the outcome predicted by the antibody titer and calculating the deviance of the
model as a measure of accuracy. Within our cohort, elevated IgM levels against
spike and RBD were reasonable predictors of experiencing malaise and fever (â€‹Fig.
1h â€‹andâ€‹ Extended Data Fig. 1fâ€“gâ€‹), but not for other symptoms (â€‹Extended Data Fig.
1hâ€‹). These results might suggest that people with strong immune responses against
the virus feel sicker during acute infection, but also have persistent IgM antibodies as
a result of this stronger antiviral response. Next, we calculated the Kendallâ€™s rank
correlation coefficient (ğœ) between symptom duration, subject age, and antibody titers
in pairs (â€‹Fig. 1iâ€‹). Beyond the strong correlation between IgG and IgM titers for both

4

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

spike and RBD, we found modest to no correlation among clinical features. Finally,
we observed no appreciable drop in antibody titers in the study population, even 60
days after active infection (â€‹Fig. 1jâ€“k â€‹andâ€‹ Extended Data Fig. 1iâ€“jâ€‹).

We sought to visualize viral transmission within our study population by generating
an undirected network of interactions based on subject exposure history (â€‹Fig. 2aâ€‹).
We limited our analysis to subjects with professional exposure plus all their adjacent
nodes. The dense and highly connected center of the network corresponds to
professional exposure, while family groups within households are arranged in the
periphery (â€‹Fig. 2aâ€‹). We observed that a large subset of our study population was
linked by an episode of professional exposure resulting in infection, however the
extent to which this event caused viral spread to subjectsâ€™ households was limited. In
fact, upon closer analysis of household groupings (â€‹Fig. 2bâ€‹) we found low levels of
transmission. Indeed, when we measured the assortativity of these household
network groups, as a proxy for viral transmission rate, we confirmed that for a
network of the size and distribution of our study the observed assortativity with
respect to serology status and IgG titers was remarkably low (â€‹Fig. 2câ€‹ - observed
assortativity in red) indicating a low transmission rate. Children (thicker edged
nodes) in particular were seldomly positive in our serology results (3/12), despite
coming into contact with infected individuals with high anti-spike IgG titres.

SARS-CoV-2 represents a unique public health challenge in modern times, with the
possibility of subsequent waves of infection being an active area of research. While
antibodies can neutralize the virus and are therefore likely to be important for

5

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

protective immunityâ€‹2â€‹, it is probable that the pathologic effects of SARS-CoV-2
infection are cell-mediated. The development of IgG antibodies during infection is
indication that a CD4â€‹+â€‹ T follicular helper cell response is mounted against this
virusâ€‹3,4â€‹, and recent work has indicated that both CD4â€‹+â€‹ and CD8â€‹+â€‹ T cells capable of
making IFN-Î³ and TNF are present within the blood of convalescent patientsâ€‹4â€“6â€‹. We
therefore decided to look broadly at cellular immune responses in convalescent
patients. We focused on both SARS-CoV-2 spike protein-specific T cell responses
and innate monocyte responses, and measured cytokines known to be produced by
both adaptive and innate immune cells. We did this for a subset of 20 convalescent
individuals in our cohort, comparing them to 20 seronegative subjects in our study
(Supp. Table 2). We purified PBMCs from these individuals and examined their
composition (â€‹Fig. 3aâ€“dâ€‹) and activation following stimulation (â€‹Fig. 3a, eâ€“hâ€‹),
correlating these results to antibody titers (â€‹Fig. 3â€‹ in bold) using conventional markers
(â€‹Extended Data Fig. 2â€‹) and 2 different stimuli (â€‹Fig. 3aâ€‹). Overall, we did not detect a
strong association between the cellular composition, immune cell activation, time
from active infection, and antibody titers, (â€‹Fig. 3â€‹ andâ€‹ Extended Data Fig.â€‹ â€‹3â€‹) with the
latter more closely associated with subject age than any other measured parameter
(â€‹Fig. 3bâ€“fâ€‹). We also observed a bimodal distribution of seropositive subjects, with
the studied population clustering in 2 separate groups (â€‹Fig. 3â€‹) indicating an
underlying complexity in our cohort. However, upon examination of TLR7-driven
classical monocyte activation (â€‹Fig. 3gâ€‹), we discovered that the percentage of
IL-6â€‹+â€‹TNFâ€‹-â€‹IL-1Î²â€‹+â€‹ monocytes clustered closely with IgG titers. Moreover, SARS-CoV-2
peptide-induced production of IL-33, IL-6, IFN-É‘2 and IL-23 in these cultures (â€‹Fig.
3hâ€‹) also clustered together with IgG titers. Critically, IL-33 production was more

6

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

closely related to IgG titers than any other measured parameter (â€‹Extended Data
Fig. 3â€‹), including subject age.

While resistance to infection is likely to involve cytokines such as IFN-Î³ produced by
T cells, many of the symptoms associated with severe COVID-19 appear to be linked
to excessive production of innate cytokines such as IL-6 and IL-1Î²â€‹7â€‹. Consequently,
we felt that the results highlighting IL-33, IL-6, IFN-É‘2, IL-23 and IL-1Î² production
(â€‹Fig. 3â€‹) could be important. In line with our clustering analysis, we found that all
highlighted features were in fact significantly increased in seropositive subjects (â€‹Fig.
4aâ€“eâ€‹). We reasoned that the observed cytokine production (â€‹Fig. 4aâ€“dâ€‹) should be a
result of T cell activation, as our experimental strategy favours this mechanism. We
found that this could be the case for IL-33, which had a strong positive correlation
with CD69 expression in CD4â€‹+â€‹ T cells (â€‹Fig. 4fâ€‹). However, this was not the case for
other parameters (â€‹Fig. 4gâ€“iâ€‹) and not unexpectedly for the percentage of
IL-6â€‹+â€‹TNFâ€‹-â€‹IL-1Î²â€‹+â€‹ monocytes (â€‹Fig. 4jâ€‹).

To our knowledge, there are no reports associating IL-33 with COVID-19 and given
the strong correlation we observed in our data we decided to explore this result in
more detail. To accomplish this, we retrieved single cell RNA sequencing data from a
recent publicationâ€‹8â€‹ and processed it to interrogate â€‹IL33â€‹ expression in the setting of
SARS-CoV-2 pulmonary disease (â€‹Fig. 4kâ€“qâ€‹ andâ€‹ Extended Data Fig. 4â€‹). These data
were generated from cells in BALF of 3 healthy donors and 9 acutely SARS-CoV-2
infected patients, 3 of whom displayed mild symptoms, while the remaining 6 were
classed as severely ill (â€‹Extended Data Fig. 4â€‹). In these data, we identified 2

7

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

potential sources of IL-33 production coming from 3 distinct cell clusters (â€‹Fig. 4kâ€“lâ€‹).
Strikingly, â€‹IL33â€‹ expression was confined to SARS-CoV-2 infected patients (â€‹Fig. 4mâ€‹),
concomitant with the increased appearance of the â€‹IL33+â€‹â€‹ cell clusters as a result of
disease (â€‹Extended Data Fig. 4â€‹). â€‹IL33â€‹+â€‹ cell clusters were most likely stromal cells
(â€‹Fig. 4nâ€“qâ€‹) and are unlikely to be responsible for the IL-33 production we observed
in PBMC cultures. However, these clinical data further implicate IL-33 in COVID-19
immunobiology.

Here we show that after the resolution of infection, an innate immune cytokine
signature persists in PBMCs of convalescent subjects, characterized by induction of
IL-33 in response to T cell activation with 14-mer peptides, a peptide length
suggestive of CD4â€‹+â€‹ T cell activationâ€‹9â€‹. However, the identity and mechanism of
activation of the IL-33-producing cells in the PBMCs from convalescent individuals
remain unclear at this time. IL-33 was initially described as a cytokine produced as
an alarmin by epithelial cells to induce type 2 immune responsesâ€‹10â€‹, and of interest in
this regard, there are reports of eosinophilia, a mark of type 2 immunity, in COVID-19
patientsâ€‹11â€‹. IL-33 is also linked to lung injury, pulmonary viral infections, and chronic
lung diseasesâ€‹12â€‹. COVID-19 can cause complications such as pneumonia and acute
respiratory distress syndrome, as well as invoke lasting damage to lungs, including
lung remodeling and fibrosis, which are consistent with known roles of IL-33â€‹13â€‹. These
observations suggest that IL-33 could participate in the pathogenesis of COVID-19.
On the other hand, IL-33 has also been reported to promote antiviral cytotoxic T cell
responsesâ€‹14â€“16â€‹ and higher antibody productionâ€‹17,18â€‹. Thus the presence of a persistent
population of cells capable of making IL-33 in response to T cell activation may

8

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

confer an advantage in the case of secondary exposure. Further work on IL-33 will
be needed to elucidate the role of this cytokine in COVID-19.

9

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES
1.

Amanat, F. â€‹et al.â€‹ A serological assay to detect SARS-CoV-2 seroconversion in
humans. â€‹medRxivâ€‹ (2020) doi:â€‹10.1101/2020.03.17.20037713â€‹.

2.

Huang, A. T. â€‹et al.â€‹ A systematic review of antibody mediated immunity to
coronaviruses: antibody kinetics, correlates of protection, and association of
antibody responses with severity of disease. â€‹medRxivâ€‹ (2020)
doi:â€‹10.1101/2020.04.14.20065771â€‹.

3.

Thevarajan, I. â€‹et al.â€‹ Breadth of concomitant immune responses prior to patient
recovery: a case report of non-severe COVID-19. â€‹Nat. Med.â€‹ â€‹26â€‹, 453â€“455
(2020).

4.

Mathew, D. â€‹et al.â€‹ Deep immune profiling of COVID-19 patients reveals patient
heterogeneity and distinct immunotypes with implications for therapeutic
interventions. doi:â€‹10.1101/2020.05.20.106401â€‹.

5.

Sekine, T. â€‹et al.â€‹ Robust T cell immunity in convalescent individuals with
asymptomatic or mild COVID-19. doi:â€‹10.1101/2020.06.29.174888â€‹.

6.

Peng, Y. â€‹et al.â€‹ Broad and strong memory CD4+ and CD8+ T cells induced by
SARS-CoV-2 in UK convalescent COVID-19 patients. â€‹bioRxiv
2020.06.05.134551 (2020) doi:â€‹10.1101/2020.06.05.134551â€‹.

7.

Wen, W. â€‹et al.â€‹ Immune cell profiling of COVID-19 patients in the recovery stage
by single-cell sequencing. â€‹Cell Discovâ€‹ â€‹6â€‹, 31 (2020).

8.

Liao, M. â€‹et al.â€‹ Single-cell landscape of bronchoalveolar immune cells in patients
with COVID-19. â€‹Nature Medicineâ€‹ vol. 26 842â€“844 (2020).

9.

Chicz, R. M. â€‹et al.â€‹ Predominant naturally processed peptides bound to HLA-DR1
are derived from MHC-related molecules and are heterogeneous in size. â€‹Nature

10

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

358â€‹, 764â€“768 (1992).
10. Molofsky, A. B., Savage, A. K. & Locksley, R. M. Interleukin-33 in Tissue
Homeostasis, Injury, and Inflammation. â€‹Immunityâ€‹ â€‹42â€‹, 1005â€“1019 (2015).
11. Gong, J. â€‹et al.â€‹ Correlation Analysis Between Disease Severity and
Inflammation-related Parameters in Patients with COVID-19 Pneumonia.
doi:â€‹10.1101/2020.02.25.20025643â€‹.
12. Werder, R. B. â€‹et al.â€‹ Chronic IL-33 expression predisposes to virus-induced
asthma exacerbations by increasing type 2 inflammation and dampening
antiviral immunity. â€‹J. Allergy Clin. Immunol.â€‹ â€‹141â€‹, 1607â€“1619.e9 (2018).
13. Guan, W.-J. â€‹et al.â€‹ Clinical Characteristics of Coronavirus Disease 2019 in China.
N. Engl. J. Med.â€‹ â€‹382â€‹, 1708â€“1720 (2020).
14. Villarreal, D. O. â€‹et al.â€‹ Alarmin IL-33 acts as an immunoadjuvant to enhance
antigen-specific tumor immunity. â€‹Cancer Res.â€‹ â€‹74â€‹, 1789â€“1800 (2014).
15. Bonilla, W. V. â€‹et al.â€‹ The alarmin interleukin-33 drives protective antiviral CD8â€‹+â€‹ T
cell responses. â€‹Scienceâ€‹ â€‹335â€‹, 984â€“989 (2012).
16. McLaren, J. E. â€‹et al.â€‹ IL-33 Augments Virus-Specific Memory T Cell Inflation and
Potentiates the Efficacy of an Attenuated Cytomegalovirus-Based Vaccine. â€‹J.
Immunol.â€‹ â€‹202â€‹, 943â€“955 (2019).
17. Sarkar, S. â€‹et al.â€‹ IL-33 enhances the kinetics and quality of the antibody
response to a DNA and protein-based HIV-1 Env vaccine. â€‹Vaccineâ€‹ â€‹37â€‹,
2322â€“2330 (2019).
18. Kayamuro, H. â€‹et al.â€‹ Interleukin-1 family cytokines as mucosal vaccine adjuvants
for induction of protective immunity against influenza virus. â€‹J. Virol.â€‹ â€‹84â€‹,
12703â€“12712 (2010).

11

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

19. Stuart, T. â€‹et al.â€‹ Comprehensive Integration of Single-Cell Data. â€‹Cellâ€‹ â€‹177â€‹,
1888â€“1902.e21 (2019).
20. Hafemeister, C. & Satija, R. Normalization and variance stabilization of
single-cell RNA-seq data using regularized negative binomial regression.
Genome Biol.â€‹ â€‹20â€‹, 1â€“15 (2019).
21. McInnes, L., Healy, J., Saul, N. & GroÃŸberger, L. UMAP: Uniform Manifold
Approximation and Projection. â€‹Journal of Open Source Softwareâ€‹ vol. 3 861
(2018).

12

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1. Serological characterization of study population.

aâ€‹, Anti-spike IgG titers shown as area under titration curve (AUC) in sera from
investigated subjects grouped by SARS-CoV-2 PCR status (Negative, None,
Positive) plus pre-pandemic historical sera (Preexp). Dotted lines illustrate estimated
thresholds above which subjects were classified as â€œBorderline caseâ€ (mean + 2xSD

13

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

â€“ red) or â€œSeropositiveâ€ (mean + 3xSD â€“ black). Mean and SD were calculated for all
IgG titers below maximum value measured from Preexp sera.

bâ€“gâ€‹, Anti-spike (b, d, f) and anti-RBD (c, e, g) IgG titers shown as AUC for
investigated subjects grouped by SARS-CoV-2 PCR status (bâ€“c), reported
symptoms (dâ€“e) and sex (fâ€“g). Subjects are colored by serology results.

hâ€‹, Detected antibody titers were used to fit logistic regression models to symptom
reporting by seropositive subjects. Deviance from logistic model fitting is shown as a
measure of model accuracy.

iâ€‹, Detected antibody titers from seropositive subjects were correlated to each other,
symptom duration and subject age using a Kendall rank correlation. A heatmap of
the Kendall rank correlation coefficient (ğœ) is shown for each pair of variables.

jâ€“kâ€‹, Anti-spike (j) and anti-RBD (k) IgG titers shown as a function of time for
seropositive subjects. Approximated time of infection was taken as day of positive
SARS-CoV-2 PCR status.

14

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. Professional exposure, rather than household exposure, dominates
SARS-CoV-2 spread.

aâ€‹, Subjects with known professional exposure or sharing a household with subjects
with known professional exposure to SARS-CoV-2 were organized in an undirected
network. Edges connect individuals exposed to one another in a professional (central
arrangement) or household setting. Individualâ€™s anti-spike IgG titers (symbol size),
serology outcome (symbol color), age (symbol border) and sex (Symbol shape) are
illustrated in the network. Connecting edges highlight matching symptoms between
individuals.

bâ€‹, As in a but connections limited to household exposure (i.e. showing family
groups).

15

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

câ€‹, Network assortativity, used as an indication of infection transmission rate, was
calculated based on the indicated parameters for the network in b (red line) and also
after parameter randomization over 10000 permutations of the network (shown as a
distribution).

16

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3. PBMCs from convalescent and non-infected subjects differ only in
innate cytokine production profile.

17

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

aâ€“hâ€‹, PBMCs in blood collected from a subset of 20 seropositive and 20 seronegative
subjects were isolated, analyzed via flow cytometry for cellular composition (bâ€“d)
and stimulated with a SARS-CoV-2 spike peptide mix or vehicle control (eâ€“f, h), or
with TLR7 agonist Resiquimod or vehicle control (g) for indicated times (a).
Activation of CD3â€‹+â€‹CD4â€‹+â€‹ (e), CD3â€‹+â€‹CD8â€‹+â€‹ (f) and CD14â€‹hiâ€‹CD16â€‹-â€‹ cells (g) plus cytokine
secretion into culture media (h) were measured via flow cytometry. Control corrected
(treatment - control) scaled data (

xi âˆ’Î¼
Ïƒ

) was then visualized as heatmaps. Scaled

anti-spike and anti-RBD IgG titers plus subject age were included in results. Data
was clustered based on Euclidean distances between features (rows) or subjects
(columns), with clusters indicated with dendrograms. Serology results are included
for each subject (seropositive â€“ purple; seronegative â€“ green). Closest associations
to antibody titers are highlighted in bold letters.

18

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4. IL-33 production correlates with T cell activation and disease severity
in SARS-CoV-2 infected subjects.

aâ€“eâ€‹, Cytokine production measured in the media of cultured PBMCs (aâ€“d) or via
intracellular staining of CD14â€‹hiâ€‹CD16â€‹-â€‹ monocytes from seropositive (purple) and

19

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

seronegative (green) subjects is shown as scaled values. Two tailed Mann-Whitney
U tests were calculated and resulting p value is reported.

fâ€“jâ€‹,â€‹ â€‹Scaled cytokine production versus corresponding CD4 T cell activation
(CD4â€‹+â€‹CD69â€‹+â€‹) in PBMC cultures of seropositive individuals is shown. Linear
regression curves fitted to these data (blue) alongside Râ€‹2â€‹ values are provided.

kâ€“qâ€‹,â€‹ â€‹Single cell RNA sequencing data from the bronchoalveolar lavage fluid of 3
healthy individual compared to 9 SARS-CoV-2 infected subjects with different
disease severities (3 mild; 6 severe) was retrieved from a public database
(GSE145926), grouped into cell clusters (k) and analyzed for the expression of IL-33
(l).

mâ€‹,â€‹ â€‹IL-33 expression in clusters 23, 27 and 30 presented as a violin plot grouped by
disease status.

nâ€“qâ€‹, Key surface (nâ€“o) and lineage specific (pâ€“q) genes expressed in IL-33
producing cells.

20

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

METHODS
Human subjects
All procedures involving human subjects were approved by the Ethics Committee of
the Medical Center - University of Freiburg (305/20). The study was registered at the
German Clinical Trial Register (â€‹DRKS00022292â€‹). Pre-exposure donor serum
samples (n=16) had been collected, aliquoted and stored at the Medical Center University of Freiburg prior to June 1st, 2019. These individuals were considered to
be pre-exposure controls since their biological material had been stored prior to the
emergence of SARS-CoV-2. This cohort included 50% males (n=8) and 50%
females. Median age was 51 years with a range of 39â€“77 years.
SARS-CoV-2-exposed subjects (n=155) were recruited with a standardized
procedure based on assessment of inclusion and exclusion criteria. Inclusion criteria
were contact to SARS-CoV-2-infected individuals, age of at least 5 years and the
ability to provide a written informed consent. The exclusion criterium was the
presence of symptoms of an acute SARS-CoV-2 infection (fever, cough, malaise)
within the last 14 days prior to blood collection. Study participants gave their written
informed consent prior to study enrollment. For subjects <18 years of age, written
informed consent was provided by one parent. Collection of biological material was
performed at the Medical Center - University of Freiburg. Serum and peripheral
blood mononuclear cells (PBMCs) were collected at one or two time points. All
samples were de-identified and analyzed in a pseudonymized manner. Information
on demographic characteristics and disease course was provided by the subjects
using a standardized questionnaire filled at the time point of enrollment. Information
on age, sex, PCR testing for SARS-CoV-2, symptoms, symptom duration, treatment

21

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

and exposure were analyzed. The cohort included 98 females (63.2%) and 57 males
(36.8%). Median age was 36 years with a range of 5â€“79 years. Further
characteristics are included in Supplementary Table 1.

Serum asservation and ELISA
Serum was collected in tubes containing clot activators (7.5 ml) and stored at room
temperature prior to processing. Tubes were centrifuged at 2500 g for 10 min and
serum was aliquoted and stored at -20 Â°C.

Serology
Collected serum was analyzed for the presence of antibodies against SARS-CoV-2
proteins by adapting a serology assay developed in the laboratory of Dr. Florian
Krammerâ€‹1â€‹, with some alterations to the protocol. Recombinant spike protein and its
receptor binding domain (RBD) were expressed from mammalian expression
plasmids kindly donated by Dr. Krammerâ€‹1â€‹. Recombinant proteins were produced
employing the Expi293 Expression System (Thermo) following the manufacturerâ€™s
recommendations. Briefly, cells were grown to exponential phase in serum-free
optimized media, then transfected with plasmid-lipid complexes prepared with
Expifectamine. 20 h later media were supplemented with expression enhancers and
finally media containing recombinant proteins was harvested 72 h later. Proteins
were purified by passing media through Ni-NTA Sepharose columns. Purity and
identity of recombinant proteins was established by polyacrylamide gel
electrophoresis and mass spectrometry.

22

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

96-well flat bottom plates (Corning) were coated with 2 Âµg/ml of recombinant proteins
overnight at 4 Â°C. Blocking was performed with 200 Âµl/well PBS containing 0.05%
Tween-20 (PBS/T) and 3% milk for 4 h. Serum samples were diluted 1:50, 1:200,
1:800 and 1:3200 performing serial dilutions in PBS/T containing 1% milk. Serum
samples were incubated for 2 h at room temperature. Plates were washed four times
with PBS/T and incubated with an anti-human IgG or IgM secondary antibody
(dilution 1:3000, Sigma or Thermo Fisher Scientific) for 1 h at room temperature.
Plates were washed four times with PBS/T and developed using a TMB substrate kit
(Biolegend) for 5 min at room temperature. Colorimetric reaction was stopped by the
addition of 2N Hâ€‹2â€‹SOâ€‹4â€‹. Internal positive and negative standards were included on
each plate to allow for data normalization between different plates. Absorbance at
450 nm was measured using a TriStar microplate reader (Berthold Technologies).

PBMC collection
Peripheral blood from 20 seronegative and 20 seropositive subjects (based on
anti-spike IgG ELISA) was collected in EDTA-coated tubes and stored at 4 Â°C prior
to processing. Blood was diluted 1:1 with PBS containing 2% FCS and 1 mM EDTA.
Peripheral blood mononuclear cells (PBMCs) were isolated using a density gradient
method. Lymphoprep solution (Stem Cell) was pipetted to the bottom of SepMate-50
tubes (Stem Cell), and diluted blood carefully layered on top. After 10 min
centrifugation at 1200 x g, the upper phase containing mononuclear cells was
transferred to a new tube. PBMCs were washed twice with PBS with 2% FCS and 1
mM EDTA. After counting, cells were aliquoted, frozen in FCS containing 10%
DMSO and stored at -80 Â°C.

23

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

SARS-CoV-2 peptide stimulation
PBMCs were thawed and rested in RPMI containing 10% FCS, 100 U/ml
penicillin/streptomycin, 4 mM glutamine and 55 ÂµM 2-mercaptoethanol for 2 h. 4x10â€‹5
PBMCs were incubated with 2 Âµg/ml SARS-CoV-2 spike PepMix (JPT) or DMSO
control in the presence of 2 Âµg/ml anti-CD28 and 50 U/ml hIL-2. The PepMix
includes a total of 315 14-mer peptides covering the whole spike protein. Incubation
was performed for 24 h with addition of 5 Âµg/ml Brefeldin A (Biolegend) for the last 4
h to block cytokine secretion. DMSO controls served as negative controls.

TLR7 agonist stimulation
2x10â€‹5 â€‹PBMCs were cultured in RPMI containing 10% FCS, 100 U/ml
penicillin/streptomycin and 4 mM glutamine supplemented with 5 Âµg/ml Brefeldin A
and 5 Âµg/ml Resiquimod (Invivogen) or water control for 4 h.

Flow cytometry
Prior to cell surface staining, PBMCs were incubated with purified NA/LE Human BD
Fc block (BD, dilution 1:300) and Live/Dead Fixable Aqua or Live/Dead Fixable Blue
(both Thermo Fisher, dilution 1:1000) in FACS buffer (2% FCS and 1 mM EDTA in
PBS) for 20 min at 4 Â°C. Cells were then washed and incubated with cell surface
antibody cocktails for 30 min at 4 Â°C. Cells were washed with FACS buffer and fixed
using BD Cytofix Fixation Buffer (for intracellular cytokine staining) or eBioscience
Fixation/Permeabilization kit (for Foxp3 staining) for 20 min at room temperature. For
intracellular staining assays, cells were washed twice with 1x BD Perm/Wash buffer

24

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

or 1x eBioscience Perm/Wash buffer prior to incubation with intracellular antibody
cocktails for 45 min at room temperature. Cells were washed twice with 1x BD
Perm/Wash buffer or 1x eBioscience Perm/Wash buffer and resuspended in FACS
buffer. Flow cytometry data were acquired on a BD LSRFortessa or BD
FACSymphony flow cytometer.

Cytokine measurement
Supernatants from PBMCs cultured with SARS-CoV-2 PepMix or DMSO control as
described above were collected and stored at -20 Â°C. Cytokines in culture media
were detected using the Legendplexâ„¢ Human Inflammation Panel 1 (Biolegend,
Cat# 740809) following the manufacturer's instructions. This kit allows for
simultaneous measurement of IL-1Î², IFNÎ±2, IFNÎ³, TNF, MCP-1, IL-6, IL-8, IL-10,
IL-12p70, IL-17A, IL-18, IL-23 and IL-33. Briefly, standards and cell culture
supernatants were incubated on a 96-well V-bottom plate with capture beads for 2 h.
The plate was washed and biotinylated detection antibodies were added to each well
for 1 h, followed by Streptavidin-phycoerythrin (PE) addition for 30 min. Samples
were washed and resuspended in FACS buffer. All steps were carried out at room
temperature. Results were obtained using a BD LSRFortessa flow cytometer. Data
analysis was performed in FlowJo. Cytokines were identified based on the size and
internal dye of the beads. Cytokine concentration in samples was derived from the
geometric mean fluorescence intensity for PE interpolated from standard curves
calculated from 8 standard controls measured in duplicate.

Data analysis and Statistics

25

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Flow cytometry data were analyzed using FlowJo version 10.6. Clinical data, ELISA
readings, flow cytometry results and single cell RNA sequencing data were
processed and analyzed using R (Lucent Technologies), which was also employed
to generate graphs.

Antibody titers:
Background measurements were subtracted from absorbance readings, which were
then batch corrected based on internal standards included on each plate. Batch and
background corrected data were then used to calculate the area under the dilution
curve (AUC) for each subject. To calculate a seropositivity threshold, a subset of
AUC values was extracted, composed of all pre-pandemic sera as well as those
subjects with an AUC lower than the maximum obtained from pre-exposure sera and
with no SARS-CoV-2 PCR or with a negative PCR result. Borderline cases were
defined as being 2 standard deviations away from the mean AUC from this sample
subset, while AUC results at least 3 standard deviations away from the mean were
taken as seropositive. All other values were defined as seronegative.

Symptoms, age and titer associations:
The relationship between antibody titers, subject age and reported symptoms were
explored in two parallel ways. First, antibody titers were used to fit a logistic
regression model capable of predicting the presence of reported symptoms (yes = 1,
no = 0). The deviance of each model was used to estimate the quality of the fit. Next,
antibody titers, subject age, and symptom duration in days were correlated with one
another using Kendallâ€™s rank correlation and reporting ğœ as the correlation coefficient.

26

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Only complete pairs of observations were used in correlations and all data was
scaled by subtracting the mean of each feature and dividing by the corresponding
standard deviation.

Network analysis:
An adjacency matrix was generated for the network of subject interactions based on
reported exposures. Subjects with suspected professional exposure to SARS-CoV-2,
who shared a workplace, were connected to each other. Subjects belonging to the
households of professionally exposed individuals were added to the network, with
interactions within households included. Only subjects with known professional
exposure and with at least one household connection were included in this analysis.
To estimate viral transmission within households, a network was constructed
exclusively with household interactions and later the assortativity of the network was
estimated with regards to serological results and antibody titers. Observed
assortativities were compared to those calculated based on 10000 permutations of
used values over the same network architecture. Network visualization, analysis and
construction was performed with igraph v.1.2.5.

Immunophenotyping clustering and regression
Flow cytometry results were collected and stimulation controls were subtracted from
values obtained for treatments. Corrected values were subsequently scaled and
clustered based on Euclidean distances to antibody titers and subject age, which
were similarly scaled. Heatmaps and clustering were obtained by using pheatmap
v.1.0.12. Selected features were correlated with one another using a linear

27

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

regression model (y ~ x) and reporting R squared as an indication of the quality of
the fit.

Single cell RNA sequencing analysis:
The transcriptional profiles of ~90000 single cells in bronchoalveolar lavage fluid
from 3 healthy individuals and 9 SARS-CoV-2 infected patients (3 with mild and 6
with severe disease) were retrieved from a publicly available repository
(GSE145926). Matrices with raw unfiltered read counts for detected features in
barcoded cells were downloaded for each subject and subsequently processed,
analyzed and visualized in R using Seurat v. 3â€‹19â€‹, removing cells with a high
percentage of mitochondrial RNA over total RNA (> 25%) and with less than 200
detected features, normalizing gene expression data by applying regularized
negative binomial regressionâ€‹20â€‹ and using a Uniform Manifold Approximation and
Projection (UMAP)â€‹21â€‹ as a dimensionality reduction approach. Differentially expressed
genes within each cluster and across conditions were determined with Seurat as
those with a greater than 1.2 fold change and an adjusted p value of less than 0.05.

28

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ACKNOWLEDGEMENTS
The authors would like to thank Yvonne Neumann, Johan FridÃ©n, Florian Krammer,
Mauro Corrado, Asifa Akhtar, Bertram Bengsch, Martin Schwemmle, Evelyn Pearce,
Constanze Waller, Fabian HÃ¤ssler, and Dan Puleston for their contributions to the
study.

AUTHOR CONTRIBUTIONS
M.A.S., D.E.S., P.A., C.F.W., E.J.P. and E.L.P designed the research, provided
conceptual input and analyzed the data. M.A.S., D.E.S., P.A., G.N., D.L. and G.M.
performed the experiments. P.A., M.H., D.S., R.T. and C.F.W. recruited participants
and collected samples plus clinical information. M.A.S., D.E.S., P.A., E.J.P. and
E.L.P wrote the manuscript.

COMPETING INTERESTS
E.L.P. and E.J.P. are founders of Rheos Medicines. E.L.P. is an SAB member of
ImmunoMet Therapeutics.

FUNDING
This study was supported by the Max Planck Society, the German Research
Foundation (DFG) Leibniz Prize (E.L.P.), and the DFG under Germany's Excellence
Strategy (CIBSS â€‹ EXC-2189 â€‹ Project ID 390939984). M.A.S. received funding from
the Swiss National Science Foundation.
Correspondence and requests for materials should be addressed to E.L.P., E.J.P. or
C.F.W.

29

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Extended Data Figure 1. â€‹Related to Figure 1: Serological characterization of study
population.

30

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

aâ€“bâ€‹, Anti-spike (a) and anti-RBD (b) IgM titers shown as AUC for investigated
subjects grouped by SARS-CoV-2 PCR status. Subjects are colored by serology
results.

câ€“eâ€‹, Indicated antibody titers are shown versus anti-spike IgG titers, with subjects
colored by serology results.

fâ€“hâ€‹, Detected antibody titers were used to fit logistic regression models to symptom
reporting by seropositive subjects. Fitted models (red lines) with low deviance
(Malaise â€“ f and Fever â€“ g) as well as with high deviance (Cough â€“ h) are shown.

iâ€“jâ€‹, Anti-spike (j) and anti-RBD (k) IgM titers shown as a function of time for
seropositive subjects. Approximated time of infection was taken as day of positive
SARS-CoV-2 PCR status.

31

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Extended Data Figure 2. â€‹Related to Figure 3: PBMCs from convalescent and
non-infected subjects differ only in innate cytokine production profile.

32

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

aâ€“eâ€‹, Gating strategies for PBMCs shown as representative flow cytometry dot plots
for lymphocytes (a), CD4â€‹+â€‹ and CD8â€‹+â€‹ memory cell populations (b), lymphocyte
cytokine production (c), monocyte populations (d) and monocyte cytokine production
(e). Control and treatments results are shown for stimulation experiments (c, e).

33

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Extended Data Figure 3. â€‹Related to Figure 3: PBMCs from convalescent and
non-infected subjects differ only in innate cytokine production profile.

34

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

aâ€“bâ€‹, PBMCs in blood collected from a subset of 20 seropositive and 20 seronegative
subjects were isolated, analyzed via flow cytometry for cellular composition and
stimulated with a SARS-CoV-2 spike peptide mix or vehicle control, or with TLR7
agonist Resiquimod or vehicle control. Activation of CD3â€‹+â€‹CD4â€‹+â€‹, CD3â€‹+â€‹CD8â€‹+â€‹ and
CD14â€‹hiâ€‹CD16â€‹-â€‹ cells plus cytokine secretion into culture media were measured via flow
cytometry. Control corrected (treatment - control) scaled data () is shown in a single
clustered heatmap, where scaled anti-spike and anti-RBD IgG titers plus subject age
are included (a), or where serpositive subjects are sorted based on time between
SARS-CoV-2 positive PCR status and PBMC collection (b). Data was clustered
based on Euclidean distances between features (rows) or subjects (columns), with
clusters indicated with dendrograms. Serology results are included for each subject
(seropositive â€“ purple; seronegative â€“ green) and a time scale is provided. Features
most closely associated with antibody titers are highlighted in bold letters.

35

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Extended Data Figure 4. â€‹Related to Figure 4: IL-33 production correlates with T cell
activation and disease severity SARS-CoV-2 in infected subjects.

aâ€‹, Single cell RNA sequencing data from the bronchoalveolar lavage fluid of 3
healthy individual compared to 9 SARS-CoV-2 infected subjects with different
disease severities (3 mild; 6 severe) was retrieved from a public database
(GSE145926), grouped into cell clusters and shown here by disease status.

36

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Table 1. â€‹Demographics and disease characteristics serology
cohorts

Characteristic

IgG serology
cohort

IgM serology
cohort

No. participants

155

122

Median age (range), years

36 (5â€“79)

34 (5â€“62)

female - no. (%)
male - no. (%)

98 (63.2)
57 (36.8)

77 (63.1)
45 (36.9)

0-17
>18

14 (9)
141 (91)

13 (10.7)
109 (89.3)

99 (64.5)
44 (28.4)
7 (3.9)
5 (3.2)

82 (67.2)
30 (24.5)
5 (4.1)
5 (4.1)

Symptoms in the last 16 weeks prior
serology - no. (%)

97 (62.6)

74 (60.7)

Median duration of symptoms - days
(range)

10 (1â€“63)

11 (1â€“55)

47 (30.3)
40 (25.8)
68 (43.9)

38 (31.1)
32 (26.2)
52 (42.7)

49 (10â€“84)

45.5 (10â€“61)

65 (41.9)
6 (1â€“21)

50 (41)
6 (1â€“21)

Demographics

Sex

Age

Disease characteristics
Exposure
Professional
Household
Professional and household
Other

SARS-CoV2 PCR
Positive - no. (%)
Negative - no. (%)
Not performed - no. (%)
Median time between positive PCR and
positive serology - days (range)
Symptoms
Cephalgia
Prevalence - no. (%)
Median duration - days (range)

37

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Malaise
Prevalence - no. (%)
Median duration - days (range)

63 (40.6%)
10 (1â€“63)

46 (37.7)
10 (1â€“48)

Prevalence - no. (%)
Median duration - days (range)

55 (35.5)
7 (1â€“21)

42 (34.4)
7 (1â€“20)

Prevalence - no. (%)
Median duration - days (range)

49 (31.6)
4 (1â€“45)

34 (27.9)
4 (1â€“14)

Musculoskeletal pain
Prevalence - no. (%)
Median duration - days (range)

43 (27.7)
7 (1â€“18)

30 (24.5)
6.5 (1â€“18)

Anosmia
Prevalence - no. (%)
Median duration - days (range)

40 (25.8)
7.5 (2â€“55)

29 (23.8)
14 (1â€“55)

Pharyngitis
Prevalence - no. (%)
Median duration - days (range)

37 (23.9)
3.5 (1â€“20)

31 (25.4)
2.75 (1â€“14)

Dyspnea
Prevalence - no. (%)
Median duration - days (range)

30 (19.4)
10 (1â€“21)

24 (19.7)
10 (1â€“21)

Weight loss
Prevalence - no. (%)
Median value - kg (range)

24 (15.5)
3.5 (1â€“10)

17 (13.9)
4.25 (1â€“10)

Hospitalization

3 (1.9)

1 (0.8)

Medication
Hydroxychloroquine
Antipyretics

2 (1.3)
17 (11)

1 (0.8)
14 (11.5)

Cough

Fever

Treatment

38

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Table 2. â€‹Demographics and disease characteristics PBMC analysis
cohorts

Characteristic

Seropositive
cohort

Seronegative
cohort

No. participants

20

20

Median age (range), years

51.5 (14â€“58)

37.5 (19â€“75)

9 (45)
11 (55)

12 (60)
8 (40)

15.5 (3â€“55)

0 (0â€“21)

SARS-CoV2 PCR
Positive - no. (%)
Negative - no. (%)
Not performed - no. (%)

18 (90)
0 (0)
2 (10)

0 (0)
8 (40)
12 (60)

SARS-CoV2 anti-Spike IgG
Positive - no. (%)
Negative - no. (%)

20 (100)
0 (0)

0 (0)
20 (100)

66 (29â€“85)

n.a.

Demographics

Sex
female - no. (%)
male - no. (%)
Disease characteristics
Median duration of symptoms - days
(range)

Median time between positive PCR and
PBMC collection - days (range)

39

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Table 3. â€‹Key reagents

Reagent

Company

Identifier

Antibodies for ELISA
Goat anti-Human IgG (H+L) Secondary ThermoFisher Cat# 31410
Antibody, HRP
Scientific
Anti-Human IgM (Î¼-chain
specific)âˆ’Peroxidase antibody
produced in goat

Sigma

Cat# A0420-1ml

Lymphoprep

Stem Cell

Cat# 07851

SepMate 50 ml tube

Stem Cell

Cat# 85450

PepMix SARS-CoV2 Spike
Glycoprotein

JPT

PM-WCPV-S-1

PepMix HCMVA (pp65)

JPT

PM-PP65-2

AlexaFluor647 anti-human CD3

Biolegend

Clone: HIT3a
Cat# 300322

PE anti-human CD3

Biolegend

Clone: HIT3a
Cat# 300308

BrilliantViolet 711 anti-human CD4

Biolegend

Clone: OKT4
Cat# 317440

FITC anti-human CD4

Biolegend

Clone: A161A1
Cat# 357406

Pacific Blue anti-human CD8

Biolegend

Clone: HIT8a
Cat# 300928

Materials for PBMC isolation

Virus peptide mixes

Antibodies for flow cytometry

40

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

APC anti-human CD8

Biolegend

Clone: HIT8a
Cat# 300812

BrilliantViolet 510 anti-human CD14

Biolegend

Clone: M5E2
Cat# 301842

APC-Cy7 anti-human CD14

Biolegend

Clone: M5E2
Cat# 301820

BrilliantViolet 605 anti-human CD16

Biolegend

Clone: 3G8
Cat# 302039

APC-Cy7 anti-human CD16

Biolegend

Clone: 3G8
Cat# 302017

PE anti-human CD19

Biolegend

Clone: HIB19
Cat# 302208

APC-Cy7 anti-human CD19

Biolegend

Clone: HIB19
Cat# 302217

PE/Dazzle 594 anti-human CD27

Biolegend

Clone: M-T271
Cat# 356421

PE-Cy7 anti-human CD45RA

Biolegend

Clone: HI100
Cat# 304112

APC-Cy7 anti-human CD56

Biolegend

Clone: HCD56
Cat# 318332

AlexaFluor 488 anti-human CD62L

Biolegend

Clone: DREG56
Cat# 304816

BrilliantViolet 785 anti-human CD69

Biolegend

Clone: FN50
Cat# 310932

PE/Dazzle 594 anti-human CD134

Biolegend

Clone: ACT35
Cat# 350019

BrilliantViolet 785 anti-human CD197

Biolegend

Clone: G043H7
Cat# 353230

AlexaFluor 488 anti-human FOXP3

Biolegend

Clone: 206D
Cat# 320111

AlexaFluor647 anti-human IFNg

Biolegend

Clone: 4SB3
Cat# 502516

AlexaFluor700 anti-human TNF

Biolegend

Clone: MAb11
Cat# 502928

41

medRxiv preprint doi: https://doi.org/10.1101/2020.07.09.20148056; this version posted July 10, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

PE-Cy7 anti-human TNF

eBioscience

Clone: TN3-19.12
Cat# 25-7423-82

FITC anti-human IL-1 beta

eBioscience

Clone: CRM56
Cat# 11-7018-42

eFluor 450 anti-human IL-6

eBioscience

Clone: MQ2-13A5
Cat# 48-7069-42

APC anti-human IL-10

Biolegend

Clone: JES3-9D7
Cat# 501409

Other reagents for flow cytometry
Live/Dead Fixable Aqua Dead Cell
Stain Kit

ThermoFisher Cat# 34957
Scientific

Live/Dead Fixable Blue Dead Cell
Stain Kit

ThermoFisher Cat# L34962
Scientific

Purified NA/LE Human BD Fc block

BD

Cat# 564765

TMB substrate set

Biolegend

Cat# 421101

Foxp3/Transcription factor staining
buffer set

eBioscience

Cat# 00-5523-00

Fixation/Permeabilization Solution Kit

BD

Cat# 554714

LEGENDplex Human Inflammation
Panel 1

Biolegend

Cat# 740809

Commercial kits

42

